Nebulized liposomal amikacin for the treatment of<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis patients

Ehsan, Zarmina; Wetzel, J Denise; Clancy, John

doi:10.1517/13543784.2014.895322

Cited by 24 publications

(8 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An attractive feature of the liposome is its breakdown by bacterial rhamnolipids, effectively meaning the drug becomes activated at the site of need. In both phase II and III trials similar increases in FEV 1 were seen as for tobramycin [Clancy et al 2013; Ehsan et al 2014]. Levofloxacin inhalation solution (MP-376) has recently been shown to be well tolerated and noninferior to tobramycin [Stuart Elborn et al 2015].…”

Section: Anti-infective Agentsmentioning

confidence: 99%

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Edmondson

Davies

2016

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Treatment for cystic fibrosis (CF) has conventionally targeted downstream consequences of the defect such as mucus plugging and infection. More recently, significant advances have been made in treating the root cause of the disease, namely a defective CF transmembrane conductance regulator (CFTR) gene. This review summarizes current pulmonary treatment options and highlights advances in research and development of new therapies

show abstract

Section: Anti-infective Agentsmentioning

confidence: 99%

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Edmondson

Davies

2016

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…Compared to other inhalation devices, nebulisers can generate large volumes of ‘respirable’ aerosol, with no need to perform drying procedures, as in the case of DPIs, or involve propellants, as in case of pMDIs [ 16 , 50 , 54 ]. Nebulisers are the most commonly used inhalation devices for the delivery of liposomes [ 7 , 8 , 9 , 55 , 56 ]. There are three types of nebuliser: air jet, ultrasonic and vibrating mesh.…”

Section: Devices Used For the Pulmonary Delivery Of Liposomesmentioning

confidence: 99%

Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications

et al. 2016

View full text Add to dashboard Cite

This is a critical review on research conducted in the field of pulmonary delivery of liposomes. Issues relating to the mechanism of nebulisation and liposome composition were appraised and correlated with literature reports of liposome formulations used in clinical trials to understand the role of liposome size and composition on therapeutic outcome. A major highlight was liposome inhalation for the treatment of lung cancers. Many in vivo studies that explored the potential of liposomes as anticancer carrier systems were evaluated, including animal studies and clinical trials. Liposomes can entrap anticancer drugs and localise their action in the lung following pulmonary delivery. The safety of inhaled liposomes incorporating anticancer drugs depends on the anticancer agent used and the amount of drug delivered to the target cancer in the lung. The difficulty of efficient targeting of liposomal anticancer aerosols to the cancerous tissues within the lung may result in low doses reaching the target site. Overall,following the success of liposomes as inhalable carriers in the treatment of lung infections, it is expected that more focus from research and development will be given to designing inhalable liposome carriers for the treatment of other lung diseases, including pulmonary cancers. The successful development of anticancer liposomes for inhalation may depend on the future development of effective aerosolisation devices and better targeted liposomes to maximise the benefit of therapy and reduce the potential for local and systemic adverse effects.

show abstract

“…Amikacin has a cationic charge and is encapsulated in neutral phospholipid/cholesterol liposomes (300 nm in diameter) to prevent interaction with mucins carrying anionic charges. 15 Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair (ClinicalTrials.gov Identifier: NCT02128646)…”

Section: Study Of Thermodox With Standardized Radiofrequency Ablationmentioning

confidence: 99%

Recent Trends in Clinical Trials Related to Carrier-Based Drugs

Tagami

Ozeki

2017

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Nebulized liposomal amikacin for the treatment ofPseudomonas aeruginosainfection in cystic fibrosis patients

Cited by 24 publications

References 42 publications

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications

Recent Trends in Clinical Trials Related to Carrier-Based Drugs

Contact Info

Product

Resources

About